Home › Non-Small Cell Lung Cancer › New York › New York City
Non-Small Cell Lung Cancer clinical trials in New York City, NY
121 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of ZW251 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RecruitingPhase 2
- New York Proton Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Local Institution - 0080, New York
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RecruitingPhase 3
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216), New York
- Icahn School of Medicine at Mount Sinai ( Site 0116), New York
- Memorial Sloan Kettering Cancer Center ( Site 0137), New York
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
RecruitingPhase 2/3
- NYU Langone Hospital Manhattan, New York
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RecruitingPhase 3
- New York Cancer & Blood Specialists - Cancer Center - Research Headquarters, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Hospital, New York
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 2
- NYU, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RecruitingPhase 3
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecruitingPhase 1
- Research Site, New York
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- NYU Langone Medical Center, New York
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, New York
- Research Site, New York
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 1/2
- New York University Langone Medical Center, New York
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Recruiting
- Weill Cornell Medicine, New York
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- Veterans Affairs New York Harbor Healthcare System, New York
An External Control Arm Study in Non-Small Cell Lung Cancer
RecruitingObservational study
- New York Cancer and Blood Specialists, New York
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RecruitingPhase 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, New York
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
RecruitingPhase 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RecruitingPhase 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RecruitingPhase 1/2
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Using Urine Samples to Identify Lung Cancer
RecruitingObservational studyHealthy volunteers welcome
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RecruitingPhase 1/2
- Mount Sinai, New York
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
RecruitingPhase 1/2
- NYU Cancer Center, New York
- Mount SInai Medical Center, New York
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Manhattan Eye, Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RecruitingPhase 1
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
- David H Koch, Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Hospital, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RecruitingPhase 3
- Research Site, New York
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
- Icahn School of Medicine at Mount Sinai PRIME, New York
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- New York Proton Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecruitingPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RecruitingPhase 1
- Weill Cornell Medicine, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
RecruitingPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RecruitingPhase 1/2
- Icahn School of Medicine at Mount Sinai, New York
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 3
- Mount Sinai Chelsea, New York
- Mount Sinai West, New York
- Mount Sinai Hospital, New York
- and 2 more
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecruitingPhase 1/2
- New York University Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- New York University Langone Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- New York Cancer & Blood Specialists (NYCBS), New York
A Study of LY4175408 in Participants With Advanced Cancer
RecruitingPhase 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
RecruitingPhase 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Pembrolizumab for Advanced NSCLC and PS 2-3
RecruitingPhase 2
- Mount Sinai Hospital, New York
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- NYU Langone Medical Center, New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecruitingPhase 1
- Research Site, New York
- Research Site, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RecruitingPhase 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
RecruitingPhase 2
- NYU Langone Health, New York
- Columbia University, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RecruitingPhase 2
- USA04-0, New York
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Research Site, New York
Lung Cancer Biomarkers and Screening
RecruitingObservational studyHealthy volunteers welcome
- NYU Cancer Institute at New York University Medical Center, New York
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
RecruitingPhase 2
- NYU Langone - NYU Grossman School of Medicine, New York
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
RecruitingPhase 2
- Perlmutter Cancer Center - 34th Street, New York
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RecruitingPhase 2
- Weill Cornell Medicine, New York
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Confocal Laser Endomicroscopy VERification
Recruiting
- Montefiore Medical Center, New York
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Phase II Trial of Lung Chemoemobolization
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Herbert Irving Comprehensive Cancer Center, New York
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
GEMINI-NSCLC: NSCLC Biomarker Study
RecruitingObservational study
- Icahn School of Medicine at Mount Sinai, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- NYU Langone Health, New York
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
RecruitingPhase 1
- Research Site, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecruitingPhase 1/2
- NYU Langone Health, New York
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center, New York
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
- Seattle, WA53 studies
Other studies in New York City
- Breast Cancer136 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
- Heart Failure51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.